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SHORT COMMUNICATION
RT-QuIC-based detection of alpha-synuclein seeding activity in brains of
dementia with Lewy Body patients and of a transgenic mouse model of
synucleinopathy
Jung-Youn Hana*, Hyung-Sup Janga*, Alison J. E. Greenb, and Young Pyo Choia
aLaboratory Animal Center, Division of Research Strategy, Korea Brain Research Institute, Daegu, Republic of Korea; bNational CJD Research &
Surveillance Unit, Centre for Clinical Brain Sciences, School of Clinical Sciences, University of Edinburgh, Edinburgh, UK
ABSTRACT
RT-QuIC is a shaking-based cyclic amplification technique originally developed in the prion field to
detect minute amounts of scrapie prion protein (PrPSc). In this study, we applied the RT-QuIC assay
to investigate a-synuclein (a-syn) seeding activity in brains of Dementia with Lewy Body (DLB)
patients and in brains of G2-3 transgenic mice expressing human a-syn with A53T mutation. The
results show that a-syn seeding activity varies between patients with detectable dilutions ranging
from 10−3 to 10−8 dilutions of brain tissue and is stable under exposures to the cycles of freezing,
thawing and sonication. A53T a-syn aggregates from G2-3 transgenic mice greatly favoured A53T
recombinant human a-syn as substrates in comparison to wild-type a-syn, suggesting that con-
formations for wild-type a-syn to be able to adopt are not compatible with that of A53T
aggregates from G2-3.
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Introduction
Alpha-synuclein (a-syn) is a well-conserved, soluble
and natively unfolded protein consisting of 140 amino
acids that is highly expressed in the nervous tissue [1].
a-syn is predominantly localized to the presynaptic
nerve terminals and thus thought to be play an impor-
tant role in synaptic vesicle biology [2,3]. a-synucleino-
pathies, which include Parkinson’s disease (PD),
dementia with Lewy bodies (DLB) and multiple system
atrophy (MSA), are characterized by the accumulation
of phosphorylated, insoluble a-syn aggregates in neuro-
nal or glial cells [3,4]. While these a-syn deposits are
found as glial cytoplasmic inclusions in MSA [5,6], they
are present in neuronal cell bodies and in dystrophic
neurites of selected population of neurons (known as
Lewy bodies and Lewy neuritis, respectively) in PD and
DLB [7]. Several missense mutations in the SNCA gene
that encodes for a-syn, and duplications or triplications
of the wild-type SNCA gene were all found to be asso-
ciated with familial PD and/or DLB [8–12].
It has been shown that fibrillar a-syn aggregates can
replicate by conferring their disease-associated confor-
mation to native a-syn [13]. The replication and spread
of a-syn aggregates along neuroanatomically connected
regions results in a stereotypical progression of Lewy
pathology in diseased human brains [14]. This prion-
like propagation of a-syn fibrils has been extensively
investigated by inducing a-synucleinopathies in animal
models [15,16] as well as in cultured cells [17,18].
Notably, as in prions, the presence of distinct a-syn
strains has been demonstrated in transmission studies
of a-synucleinopathies into cultured cells and/or trans-
genic mice [19,20].
RT-QuIC (real-time quaking-induced conversion) is
a highly sensitive biochemical assay originally devel-
oped in the prion field to detect minute amounts of
scrapie prion protein (PrPSc) in brain tissue or body
fluids [21,22]. In the RT-QuIC assay, a mixture of test
specimen and recombinant prion protein in a multiwell
plate is intermittently shaken to amplify prion protein
aggregates in a seed-dependent manner [23]. Real-time
monitoring of fluorescence signal of thioflavin T (ThT)
that binds to β-sheet-rich structures in amyloid fibrils
allows the detection of prion seeding activity in tested
samples [24]. In recent years, successful adaptation of
the RT-QuIC assay for a-synucleinopathies has been
reported by several groups [25–28]. Similar to the
prion protein assay, a-syn RT-QuIC was able to detect
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a minute amount of disease-associated a-syn in tissue
lysates or in body fluids from patients with a-synuclei-
nopathies [29,30]. In this study, we investigated a-syn
seeding activity in brains of DLB patients or in brains
of transgenic mice expressing human A53T a-syn [31]
using RT-QuIC assay adapted for a-syn [26,27]. Our
results show that a-syn seeding activity is often variable
between DLB cases, and A53T a-syn aggregates from
transgenic mice greatly favours recombinant A53T
a-syn in comparison to wild-type a-syn (i.e. lacking
A53T mutation) as substrate in the seeded aggregation
assay.
Materials and methods
Human brain tissue was obtained from the Edinburgh
Brain and Tissue Bank (EBTB) in Edinburgh, Scotland,
UK. Brain samples from seven patients affected by DLB
and from six controls (Con) were used in this study
(Table 1). Frozen brain samples pseudoanonymized
using the Bank’s reference number system were sent
to Korea Brain Research Institute (KBRI) without any
patient identifiable data. Ethical approvals for the
acquisition and use of human brain samples were
obtained from KBRI’s Institutional Review Board.
Brain tissue was homogenized in nine volumes of phos-
phate-buffered saline (PBS, pH 7.4) containing com-
plete EDTA-free protease inhibitors and phosphatase
inhibitors (Roche Applied Science), by using the
Precellys 24 tissue homogenizer (Bertin instrument).
The 10% (w/v) homogenates were clarified by centrifu-
gation at 2,000 × g for 2 min and the supernatants were
transferred to new tubes and kept in aliquots at −80°C
until investigated. Unless specified otherwise, the ali-
quots were used only once after thawing and any
remaining ones were discarded.
The transgenic mouse line G2-3 expressing human
a-syn with A53T mutation under the control of murine
prion protein promoter was described previously
[31,32]. The use of G2-3 mice was approved by
KBRI’s Institutional Animal Care and Use Committee.
Mice transgenic for human A53T a-syn and non-carrier
controls were euthanized at 10–11 months, and their
brains were recovered. Caudal parts (brainstem, pons
and midbrain) of these brains were separated and
homogenized as described above. Clarified brain homo-
genates were stored in aliquots at −80°C until use.
RT-QuIC was performed as described previously
[26] with modifications [27]. Briefly, seeded a-syn
aggregation was conducted in 100 mM phosphate buf-
fer (pH 8.2) containing 10 μM recombinant full-length
(140 amino acids) human α-syn protein (rPeptide) and
10 μM thioflavin T (ThT) in 96-well black plates with
clear bottom (Nalgene Nunc). Recombinant human α-
syn protein (recSyn), either wild-type or A53T mutant
protein, was supplied in the form of lyophilized powder
and stored in freezer until use. On the day of experi-
ment, the recSyn was resuspended in water at
a concentration of 100 μM, filtered through a 50 kDa
filter (Millipore) for 10 min at 15,000 × g, and added to
a reaction mixture at a final concentration of 10 μM.
Any remaining resuspended recombinant a-syn solu-
tion was discarded. With regard to seeds, aliquots of
brain homogenates stored at −80°C were thawed and
extensively sonicated with 5 cycles of 30 s sonication
and 30 s rest in Microsonix 4,000 (Sonix) set at 80%
potency. Subsequently, sonicated brain homogenates
were serially diluted and used as seeds at various dilu-
tions. Dilutions were expressed in relation to brain; for
example, 10−3 dilution is equivalent to 0.1% brain
homogenate. Remaining brain homogenates after use
as seeds were discarded. In some experiments to
Table 1. Summary of the α-syn RT-QuIC assay for multiple
human brain tissue.
Case
ID Gender
Age
at
death1)
Neuropathological
diagnosis
Brain
region2)
Detectable
dilution
Con1 F 79 Cerebrovascular
disease
Frontal
cortex
10−3
Con2 M 76 Normal Frontal
cortex
ND3)
Con3 M 29 Normal Frontal
cortex
ND
Con4 M 39 Normal BA94) ND
BA39 ND
Con5 F 74 Normal BA9 ND
BA39 ND
Con65) M 83 – Frontal
cortex
ND
Thalamus ND
DLB1 M 78 DLB Frontal
cortex
10−8
Thalamus 10−5
DLB2 M 55 DLB Frontal
region
10−7
Parietal
region
10−6
DLB3 M 55 DLB Frontal
cortex
10−3
Thalamus 10−5
DLB4 F 86 DLB BA9 10−7
BA39 10−6
DLB5 M 60 DLB BA9 10−8
BA39 10−7
DLB6 M 65 DLB BA9 10−8
BA39 10−7
DLB7 M 61 DLB BA9 10−7
Parietal
region
10−7
1) Age of death in years
2) The information on brain regions were described as provided by the
EBTB.
3) ND = not detectable at 10−3 dilution
4) BA = Brodmann area
5) This case was initially sent to us as one of DLB samples. Despite multiple
RT-QuIC trials, however, a-syn seeding activity was not detectable in this
case (even at 10−2 dilution). Given that EBTB’s re-examination of the brain
tissue from this case revealed no convincing a-syn pathology, we cate-
gorized this case as control in this study.
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investigate the stability of a-syn seeding activity, soni-
cated brain homogenates were re-frozen at −80°C,
thawed after day(s) and sonicated again; this set of
freezing, thawing and sonication was repeated up to
four times. The brain homogenates exposed to the
freezing/thawing/sonication cycle from one time to
four times were serially diluted and used as seeds.
Each well of the plate preloaded with 4 glass beads
(diameter: 1.0 ~ 1.25 mm) was given 100 μL of reaction
mixture seeded with 2 μL of brain homogenates.
Reactions for individual samples were prepared in tri-
plicate. The plate was then incubated at 37°C with
cycles of 1 min shaking (400 rpm, double orbital) and
1 min rest in a FLUOstar Omega plate reader (BMG
Labtech). The plate reader measures ThT fluorescence
in relative fluorescence units (rfu) and is saturated at
260,000 rfu. ThT fluorescence was measured at
1-h intervals from bottom of wells (440 nm excitation
and 480 nm emission, gain of 2,000, 20 flashes per
well). Fluorescence values at each reading point were
shown as average for triplicate wells on the graph.
A ThT fluorescence threshold was determined as
described previously [27,33] with minor modifications,
by taking the average fluorescence of the first five read-
ings for all samples plus five standard deviations. When
wild-type recSyn and A53T recSyn were used as sub-
strate within the same plate, average fluorescence was
obtained separately based on the type of recombinant
protein. Samples were considered positive when at least
two of three replicates crossed the threshold fluorescence
value at 60th reading (approximately 60.5-h incubation).
Results
The optimal conditions of RT-QuIC assay were initially
investigated using wild-type recSyn as substrate and
frontal cortex (FC) tissue of DLB1 or Con2 brains as
seeds. While the ThT fluorescence signals from
unseeded reactions or reactions seeded with 10−3 dilu-
tion of Con2 FC tissue remained at baseline values
throughout the assay, reactions seeded with 10−3 to
10−6 dilutions of DLB1 FC tissue gave responses rising
above baseline after a lag phase of approximately 20
h (Figure 1). Positive responses for α-syn seeding activ-
ity were seen in reactions seeded with up to 10−8 dilu-
tion of DLB1, although there were much longer lag
phases and lower maximal responses in reactions
seeded with higher dilutions (10−7 to 10−8).
We then investigated RT-QuIC seeding activity in
more cases of DLB and non-demented controls using
wild-type recSyn as substrate. Positive RT-QuIC
responses were seen in all DLB cases. Maximal dilution
allowing us to detect α-syn seeding activity varied
between regions within the same brain as well as
between DLB cases, ranging from 10−3 to 10−8 dilutions
of the brain tissue (Table 1). Reactions seeded with
brain homogenates prepared from control cases gave
flat responses in the assay, except for one case (Con1)
in which seeding activity was detectable at a 10−3 dilu-
tion of the brain tissue (Table 1).
Next, in order to examine the stability of a-syn
seeding activity under laboratory conditions, FC brain
homogenates from DLB1 or Con2 patient were exposed
Figure 1. RT-QuIC detection of a-syn seeding activity in DLB using wild-type human a-syn as substrate. Serial dilutions (10−3 to 10−8)
of human frontal cortex brain tissue derived from a DLB patient (DLB1) were used to seed RT-QuIC reactions with wild-type recSyn as
substrate. Reactions seeded with 10−3 dilution of frontal cortex tissue from a non-demented patient (Con2) were included as
controls. Unseeded reactions are also shown. ThT fluorescence was measured every 1 h and average values from triplicate wells were
plotted as a function of time.
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to the cycle of freezing, thawing and sonication up to
four times with one-day or longer intervals between
cycles. Subsequently, the DLB1 or Con2 brain homo-
genates were serially diluted and used as seeds in the
RT-QuIC assay. The kinetics of RT-QuIC reactions
seeded with 10−4 to 10−6 dilutions of the DLB1 FC
tissue was overall similar regardless of the number of
freeze/thaw cycles (Figure 2 and data not shown). It
took approximately 20 h to produce responses rising
above baseline values, and generally 30 to 40 h to reach
maximal rfu signals. These results indicate that α-syn
seeding activity in DLB brain tissue was stable and
resistant to several cycles of freezing, thawing and
laboratory-conditioned sonication.
We then investigated A53T a-syn seeding activity in
RT-QuIC using brain homogenates derived from G2-3
transgenic mice expressing human α-syn with A53T
mutation. When wild-type recSyn lacking A53T muta-
tion was used as substrate for seeded conversion in the
assay, positive responses were usually seen at 10−3 and/
or 10−4 dilutions of G2-3 mouse brains. Unlike those
seeded with DLB brain homogenates, however, reac-
tions seeded with G2-3 mouse brain homogenates gave
positive responses that were distinctively low and
inconsistent between experiments and/or replicate
wells with mostly only two of three wells rising above
background levels (Figure 3(a) and data not shown).
Since there was a mismatch at amino acid residue 53
between substrate and seed, we wondered whether this
mismatch might be associated with low and inconsis-
tent responses in the assay seeded with G2-3 brain
homogenates. To investigate this possibility, we con-
ducted a homologous RT-QuIC assay by replacing
wild-type recSyn with A53T recSyn. As shown in
Figure 3(b), a drastically different RT-QuIC response
was seen when A53T recSyn was used as substrate. In
reactions seeded with 10−3 and 10−4 dilutions of G2-3
brain tissue, the increase of ThT fluorescent signal
rising above baseline values appeared as early as 15
h and reached a plateau in 30–40 h. The reactions
seeded with higher dilutions of G2-3 seed (10−5 and
10−6) were slower and did not reach the plateau
throughout the 60-h reaction time, but their positive
responses were evident (Figure 3(b)). In the reactions
seeded with DLB brain homogenates, the kinetics of
conversion was basically similar between WT recSyn
and A53T recSyn, except for shorter lag times with
A53T recSyn (Figure 3(c,d)). It was also noticeable,
Figure 2. a-syn seeding activity detected by the RT-QuIC assay is stable after repeated freezing/thawing/sonication cycles. Aliquots
of frontal cortex brain homogenates, prepared either from DLB1 or Con2 patient, were repeatedly subjected to the cycle of freezing
(−80°C), thawing and sonication. The designated dilutions of the DLB1 (10−4 to 10−6) or Con2 (10−4) frontal cortex brain tissue
exposed to the cycle one time (a) or four times (b) were used to seed RT-QuIC reactions with wild-type recSyn as substrate. ThT
fluorescence was measured every 1 h and average values from triplicate wells were plotted as a function of time.
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however, that spontaneous positive response was occa-
sionally seen in the reactions using A53T recSyn as
substrate (Figure 3(d) and data not shown).
Discussion
RT-QuIC, which is a shaking-based cyclic amplification
technique originally developed in the prion field
[21,22,34], has been adapted for a-synucleinopathies
in recent years by several groups [26,27,30,33,35].
Using a-syn RT-QuIC, we examined a-syn seeding
activity in the brains of DLB patients. As shown in
Table 1, a-syn seeding activity was found to be often
variable between DLB brains with detectable dilutions
ranging from 10−3 to 10−8 dilutions of brain tissue. This
a-syn seeding activity was stable against repeated expo-
sures to the cycle of freezing, thawing and sonication,
which is consistent with stability and resistance of a-syn
seeds to various inactivation methods [36–38].
Nonetheless, it remains to be explored whether a-syn
seeding activity would be stable at higher dilutions of
DLB brains (for example those at 10−7 or 10−8).
We detected a-syn seeding activity in one non-
demented control brain (Con1). This brain was sent
to us as one of the non-demented controls from the
EBTB, but was found on the information sheet to have
cerebrovascular disease including lacunar infarct and
small vessel lipohyalinosis. Although the deposition of
aggregated a-syn was not recorded on this information
sheet, a-syn seeding activity in the Con1 brain may be
associated with high prevalence of a-syn pathology in
the brains of cognitively normal elderly [39]. Given that
the number and region of controlhuman brains exam-
ined in this study were relatively small and limited,
investigation of more cases of non-demented human
controls could be useful in identifying the prevalence of
pathogenic a-syn seeds in cognitively normal elderly.
RT-QuIC responses in reactions seeded with brain
homogenates from G2-3 transgenic mice expressing
A53T mutant a-syn differed markedly between two
recSyn sequences, wild-type and A53T. While homolo-
gous reactions (A53T seeds and A53T substrates) lead to
seeded aggregation with high efficiency, heterologous
reactions (A53T seeds and wild-type substrates) did not
support the conversion efficiently. In contrast, wild-type
a-syn aggregates supported the seeded conversion of both
A53T and wild-type recSyn in RT-QuIC. In vitro aggre-
gation of wild-type or A53T recSyn was known to form
morphologically and biochemically distinct fibrils [40]
and these structural properties were reported to be trans-
mitted in seeding experiments in a seed-dependent man-
ner [41,42]. In a similar context, whether conformation
favoured by soluble monomeric recSyn is compatible
with that of seeds was suggested to be a critical factor
Figure 3. A53T a-syn seeding activity in the G2-3 transgenic mouse is much more efficiently detected using recombinant A53T
recSyn than wild-type recSyn. The designated dilutions of 298 G2-3 brain tissue (a and b, 10−3 to 10−6) or the DLB5 BA9 brain tissue
(c and d, 10−5 to 10−8) were used to seed RT-QuIC reactions using wild-type (a and c) or A53T (b and d) recSyn as substrate. As
controls, reactions were also seeded with a 10−3 dilution of Con5 BA9 brain tissue or 279 non-carrier mouse brain tissue. ThT
fluorescence was measured every 1 h and average values from triplicate wells were plotted as a function of time.
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in inducing seeded aggregation [43]. Thus, the poor
ability of A53T aggregates in inducing seeded aggrega-
tion of wild-type recSyn is probably associated with con-
formational limitation for wild-type recSyn to be able to
adopt in the given condition. In comparison, given the
results in this study, the conformation of wild-type a-syn
aggregates is thought to be compatible with conforma-
tions for both wild-type and A53T recSyn to be able to
adopt in the experimental condition.
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